




# ASO Visual Abstract: Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy with or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study

Abdelkader Taibi, MD, PhD<sup>1,2</sup> , Olivia Sgarbura, MD, PhD<sup>3,4</sup>, Martin Hübner, MD, PhD<sup>5</sup>, Sylvia M. Bardet, PhD<sup>2</sup>, Mohammed Alyami, MD<sup>6,7</sup>, Naoual Bakrin, MD, PhD<sup>8</sup>, Sylvaine Durand Fontanier, MD<sup>1,2</sup>, Clarisse Eveno, MD, PhD<sup>9</sup>, Johan Gagniere, MD, PhD<sup>10</sup>, Basile Pache, MD<sup>5</sup>, Marc Pocard, MD, PhD<sup>11</sup>, François Quenet, MD<sup>3</sup>, Hugo Teixeira Farinha, MD<sup>5</sup>, Emilie Thibaudeau, MD<sup>12</sup>, Frederic Dumont, MD, PhD<sup>12</sup>, and Olivier Glehen, MD, PhD<sup>6</sup>

<sup>1</sup>Digestive Surgery Department, Dupuytren Limoges University Hospital, Limoges, France; <sup>2</sup>CNRS, XLIM, UMR 7252, University Limoges, Limoges, France; <sup>3</sup>Department of Surgical Oncology, Cancer Institute Montpellier (ICM), University of Montpellier, Montpellier, France; <sup>4</sup>IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Institut régional du Cancer de Montpellier, Université de Montpellier, Montpellier, France; <sup>5</sup>Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland; <sup>6</sup>Department of General Surgery and Surgical Oncology, Lyon Sud University Hospital, Pierre Benite, France; <sup>7</sup>Department of General Surgery and Surgical Oncology, King Khalid Hospital, Najran, Saudi Arabia; <sup>8</sup>Department of General Surgery and Surgical Oncology, Lyon Sud University Hospital, Pierre Benite, France; <sup>9</sup>Department of General Surgery, University Hospital Lille, Lille, France; <sup>10</sup>Department of General Surgery, University Hospital Clermont-Ferrand, Clermont-Ferrand, France; <sup>11</sup>INSERM U1275, CAP Paris-Tech, Carcinomatosis Peritoneum Paris Technology, Lariboisière Hospital, AP-HP, Paris 7-Diderot University, Sorbonne Paris Cité, Paris, France; <sup>12</sup>Department of Surgical Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France

This study (<https://doi.org/10.1245/s10434-022-11577-2>) included consecutive patients with histologically proven unresectable and isolated colorectal peritoneal metastases (cPM), treated with PIPAC-Ox in seven tertiary referral centers between January 2015 and April 2020. Toxicity events and oncological outcomes (histological response, progression-free survival, and overall survival) were

compared between patients who received intraoperative intravenous 5-FU/L (PIPAC-Ox + 5-FU/L group) and patients who did not (PIPAC-Ox group). The safety and feasibility of PIPAC-Ox + 5-FU/L appear to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be evaluated in larger studies.

## Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastasis: A Multicenter Comparative Cohort Study

PIPAC-Ox group  
(n=101, nPIPAC=263)



### STUDY POPULATION



PIPAC-Ox + 5-FU/L group  
(n=30, nPIPAC=80)

43% of the patients received the preplanned protocol ( $\geq 3$  procedures)

### Feasibility


Half of the patients received the preplanned protocol

CTCAE grade  $\geq 2$  adverse events occurred in 48 of 101 (47.5%) patients



### Safety profile

CTCAE grade  $\geq 2$  adverse events occurred in 13 of 30 (43.3%) patients

### RESPONSE



Medians PCI were  
 • 21 at PIPAC-Ox#1  
 • 21 at PIPAC-Ox#3



### RESPONSE



Medians PCI were  
 • 21 at PIPAC-Ox#1  
 • 21 at PIPAC-Ox#3

**Conclusion:** The combination of intraoperative intravenous 5-FU/L with PIPAC-Ox for patients was as safe and well-tolerated as PIPAC-Ox alone

Taibi A, et al. *Ann Surg Oncol*.  
 Visual Abstract for @AnnSurgOncol

ANNALS OF  
**SURGICAL  
 ONCOLOGY**

**AUTHOR CONTRIBUTIONS** AT, FD, OG, OS, and MH conceptualization, patient management, database, methodology, writing—original draft, and review. Other authors: patient management, database, review. All authors: review.

**FUNDING** None.

**DISCLOSURES** Olivier Glehen is a consultant for Gamida. Other authors: None

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.